Adenocarcinoma

91 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Carcinoma, Neoplasms

Narrower: Adenocarcinoma of Lung 12, Adenocarcinoma, Bronchiolo-Alveolar 2, Adenocarcinoma, Clear Cell 1, Adenocarcinoma, Mucinous 6, Adenocarcinoma, Papillary 1, Carcinoid Tumor 2, Carcinoma, Acinar Cell 2, Carcinoma, Adenoid Cystic 6, Carcinoma, Intraductal, Noninfiltrating 6, Carcinoma, Medullary 1, Carcinoma, Neuroendocrine 3, Carcinoma, Signet Ring Cell 2, Cholangiocarcinoma 20, Cystadenocarcinoma, Mucinous 2, Cystadenocarcinoma, Serous 2, Eccrine Porocarcinoma 1, Klatskin Tumor 1, Paget Disease, Extramammary 3, Pseudomyxoma Peritonei 3

Treatments and conditions

Adenocarcinoma
Treatment and conditionWhere it standsTrials
5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BHB810 for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Breast Radiotherapy for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carbon ion irradiation for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Community Treatment for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + Gem/Cis for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for cholangiocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + Mevrometostat for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GALLIUM GA-68 GOZETOTIDE for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Haic+tae + tislelizumab + surufatinib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitomycin for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxcel Q3W for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PD-1antibody plus GEMOX for klatskin tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prostate Radiotherapy + Radical Prostatectomy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pulmonary segmentectomy for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Segmentectomy for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selpercatinib for carcinoma, medullaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sequential cytoreductive intervention for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SOC plus trastuzumab and pembrolizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin + Rilvegostomig for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sotorasib for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + Bemarituzumab for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + DEPATUXIZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + NIVOLUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + RAMUCIRUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + TRASTUZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tamoxifen for carcinoma, intraductal, noninfiltratingPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Tislelizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
vitamin D 25(OH)D for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for adenocarcinoma, clear cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zolbetuximab for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.